Clinical References
Foundation of Clinical Evidence
Alivora’s research is grounded in peer-reviewed clinical data and regulatory pathways.
Key references include:
- GW Pharmaceuticals. "Efficacy of cannabinoid treatment in MS-related spasticity." Lancet Neurology, 2018.
- Russo, E.B. "Cannabinoids in the management of difficult-to-treat pain." Therapeutics and Clinical Risk Management, 2008.
- FDA Orphan Drug Designation Database. Huntington’s Disease Cannabinoid Therapy, 2024.
- Pertwee, R.G. "Pharmacology of cannabinoid receptors." British Journal of Pharmacology, 2006.